TP53BP1 and inflammatory bowel disease: Most importantly, in a mouse model of IBD, a known risk-factor for CRC, intrarectal CNF1 administration induces a significantly higher count of dysplastic ACF and 53BP1 in comparison to controls, and the formation of focal adenomas, diffuse GIN and squamous metaplasias.